688222.SH上海证券交易所 · 科创板 STAR
Hitgen 成都先导
Healthcare Services 医疗服务
¥43.69−¥0.50 · −1.13%
Open 开盘
¥44.50
High 最高
¥44.70
Low 最低
¥42.61
Prev Close 昨收
¥44.19
Volume 成交量
1,612.8万股
Turnover 成交额
¥7.06亿
Mkt Cap 总市值
¥175亿
P/E 市盈率
124.9×
Recent Activity 近期动态All Filings 全部公告 →
12 significant filings since 31 May 2026: 6 on equity incentive, 3 on major holder selling and 2 on change of interest, and 1 other kind. The latest, on 24 Sep 2026: 成都先导药物开发股份有限公司关于2025年限制性股票激励计划第一个归属期归属结果暨股票上市公告.
自 31 May 2026 起有 12 份重大公告：equity incentive 6 份、major holder selling 3 份、change of interest 2 份，另有 1 类。最新一份（24 Sep 2026）：成都先导药物开发股份有限公司关于2025年限制性股票激励计划第一个归属期归属结果暨股票上市公告。
10.0020.0030.0040.0050.00
Volume 成交量
6,998.0万
20202021202320252026
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Healthcare Services 医疗服务 · 54 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥175亿 | ¥73亿 | 10th highest of 54 · 54 家中第 10 高 | |
| Trailing P/E 市盈率 | 124.9x | 102.7x | 14th highest of 38 · 38 家中第 14 高 | |
| P/B 市净率 | 11.5x | 3.4x | 5th highest of 54 · 54 家中第 5 高 | |
| Revenue Growth 营收增速 | 52.4% | 4.0% | 2nd highest of 54 · 54 家中第 2 高 | |
| Profit Growth 净利增速 | 61.2% | 3.3% | 13th highest of 54 · 54 家中第 13 高 | |
| Gross Margin 毛利率 | 54.7% | 33.3% | 4th highest of 54 · 54 家中第 4 高 | |
| Net Margin 净利率 | 23.0% | 5.8% | 6th highest of 54 · 54 家中第 6 高 | |
| Return on Equity 净资产收益率 | 5.2% | 2.0% | 10th highest of 54 · 54 家中第 10 高 | |
| Debt to Assets 资产负债率 | 23.3% | 28.7% | 21st lowest of 54 · 54 家中第 21 低 | |
| Grade Score 评级得分 | 81 | 52 | 2nd highest of 53 · 53 家中第 2 高 |
Statement figures are for the period to 30 Jun 2026, filed by 54 of 54 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，54 家同业中 54 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Wuxi Apptec 药明康德 | ¥4,912亿 | 22.7x | 5.8x | 38.9% | 38.5% | 13.2% | B |
| Pharmaron Beijing 康龙化成 | ¥796亿 | 46.5x | 4.9x | 17.9% | 9.4% | 4.6% | C |
| Aier Eye Hospital Group 爱尔眼科 | ¥731亿 | 28.7x | 3.2x | 3.8% | 12.9% | 6.0% | C |
| Asymchem Laboratories 凯莱英 | ¥647亿 | 62.4x | 3.6x | 13.1% | 14.3% | 2.9% | C |
| Biocytogen 百奥赛图 | ¥563亿 | 153.8x | 23.3x | 51.6% | 25.6% | 10.5% | B |
| Hangzhou Tigermed Consulting 泰格医药 | ¥489亿 | 535.2x | 2.5x | 14.1% | -5.0% | -2.0% | D |
| Joinn 昭衍新药 | ¥341亿 | 34.6x | 3.8x | 5.3% | 106.2% | 8.6% | B |
| Haoyuan Chemexpress 皓元医药 | ¥213亿 | 82.0x | 6.6x | 25.7% | 9.8% | 5.3% | C |
| BGI Genomics 华大基因 | ¥185亿 | — | 2.2x | 9.6% | 2.7% | 0.6% | D |
| Hitgen 成都先导 | ¥175亿 | 124.9x | 11.5x | 52.4% | 23.0% | 5.2% | B |
| Meinian Onehealth Healthcare Holdings 美年健康 | ¥173亿 | 53.2x | 2.2x | -6.4% | -5.0% | -2.2% | E |
| Topchoice Medical 通策医疗 | ¥148亿 | 24.1x | 3.6x | 4.1% | 32.8% | 9.5% | C |
| Gempharmatech 药康生物 | ¥145亿 | 79.5x | 6.4x | 22.6% | 24.1% | 4.8% | B |
| Jiuzhou Pharma 九洲药业 | ¥145亿 | 24.5x | 1.6x | -10.3% | 14.8% | 4.3% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。